Von willebrand factor improves risk prediction in addition to N-terminal pro-B-type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction

Circulation: Heart Failure

Volumn 8, Issue 1, 2015, Pages 25-32

  Kleber, Marcus E ^a   Koller, Lorenz ^c   Goliasch, Georg ^c   Sulzgruber, Patrick ^c   Scharnagl, Hubert ^d   Silbernagel, Gnther ^g   Grammer, Tanja B ^a,b   Delgado, Graciela ^a   Tomaschitz, Andreas ^e,h   Pilz, Stefan ^f   Mrz, Winfried ^a,d,i   Niessner, Alexander ^c  

^a Medical Clinic V (Nephrology Hypertensiology Endocrinology Diabetology and Rheumatology)   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Clinical Institute of Medical and Chemical Laboratory Diagnostics   (United States)

^e Division of Cardiology   (United States)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g UNIVERSITY OF BERN   (Switzerland)

^h Specialist Clinic for Rehabilitation PV Bad Aussee   (United States)

ⁱ SYNLAB ACADEMY   (Germany)

Author keywords

Diastolic heart failure; Prognosis; Von Willebrand factor

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; VON WILLEBRAND FACTOR; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; CREATININE BLOOD LEVEL; ERYTHROCYTE; EXERCISE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PATIENT REFERRAL; PHYSICAL ACTIVITY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SINUS RHYTHM; SMOKING; AUSTRIA; BLOOD; CAUSE OF DEATH; CONFIDENCE INTERVAL; HEART FAILURE; HEART STROKE VOLUME; METABOLISM; MIDDLE AGED; MORBIDITY; PHYSIOLOGY; PROCEDURES; RADIOGRAPHY; RETROSPECTIVE STUDY; SURVIVAL RATE; TRENDS;

AGED; AUSTRIA; CAUSE OF DEATH; CONFIDENCE INTERVALS; CORONARY ANGIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MORBIDITY; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STROKE VOLUME; SURVIVAL RATE; VON WILLEBRAND FACTOR;

EID: 84925022502     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.001478     Document Type: Article

References (29)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259.
2. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670-679.
3. Ho JE, Gona P, Pencina MJ, Tu JV, Austin PC, Vasan RS, Kannel WB, D'Agostino RB, Lee DS, Levy D. Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. Eur Heart J. 2012;33:1734-1741.
4. O'Donoghue M, Braunwald E. Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol. 2010;7:13-20.
5. van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, Paulus WJ, Voors AA, Hillege HL. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013;61:1498-1506.
6. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-271.
7. Akiyama E, Sugiyama S, Matsuzawa Y, Konishi M, Suzuki H, Nozaki T, Ohba K, Matsubara J, Maeda H, Horibata Y, Sakamoto K, Sugamura K, Yamamuro M, Sumida H, Kaikita K, Iwashita S, Matsui K, Kimura K, Umemura S, Ogawa H. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2012;60:1778-1786.
8. Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010;56:845-854.
9. Lenting PJ, Casari C, Christophe OD, Denis CV. von Willebrand factor: the old, the new and the unknown. J Thromb Haemost. 2012;10:2428-2437.
10. van Hinsbergh VW. Endothelium-role in regulation of coagulation and inflammation. Semin Immunopathol. 2012;34:93-106.
11. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332:635-641.
12. Gombos T, Makó V, Cervenak L, Papassotiriou J, Kunde J, Hársfalvi J, Förhécz Z, Pozsonyi Z, Borgulya G, Jánoskuti L, Prohászka Z. Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure. Thromb Haemost. 2009;102:573-580.
13. Winkelmann BR, März W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J; LURIC Study Group (LUdwigshafen RIsk and Cardiovascular Health). Rationale and design of the LURIC study-a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics. 2001;2(1 suppl 1):S1-73.
14. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11-21.
15. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4:1186-1193.
16. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005;111:363-368.
17. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cellderived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104:100-106.
18. Denis CV, André P, Saffaripour S, Wagner DD. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factordeficient mice. Proc Natl Acad Sci U S A. 2001;98:4072-4077.
19. Petri B, Broermann A, Li H, Khandoga AG, Zarbock A, Krombach F, Goerge T, Schneider SW, Jones C, Nieswandt B, Wild MK, Vestweber D. von Willebrand factor promotes leukocyte extravasation. Blood. 2010;116:4712-4719.
20. Cheng JM, Akkerhuis KM, Battes LC, van Vark LC, Hillege HL, Paulus WJ, Boersma E, Kardys I. Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail. 2013;15:1350-1362.
21. Niethammer M, Sieber M, von Haehling S, Anker SD, Munzel T, Horstick G, Genth-Zotz S. Inflammatory pathways in patients with heart failure and preserved ejection fraction. Int J Cardiol. 2008;129:111-117.
22. Koller L, Kleber M, Goliasch G, Sulzgruber P, Scharnagl H, Silbernagel G, Grammer T, Delgado G, Tomaschitz A, Pilz S, März W, Niessner A. C-reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction. Eur J Heart Fail. 2014;16:758-766.
23. Chong AY, Freestone B, Patel J, Lim HS, Hughes E, Blann AD, Lip GY. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol. 2006;97:671-675.
24. Chong AY, Lip GY. Viewpoint: the prothrombotic state in heart failure: a maladaptive inflammatory response? Eur J Heart Fail. 2007;9:124-128.
25. de Peuter OR, Kok WE, Torp-Pedersen C, Büller HR, Kamphuisen PW. Systolic heart failure: a prothrombotic state. Semin Thromb Hemost. 2009;35:497-504.
26. Chan MM, Lam CS. How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail. 2013;15:604-613.
27. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 1993;70:380-385.
28. Patel TV, Mittal BV, Keithi-Reddy SR, Duffield JS, Singh AK. Endothelial activation markers in anemic non-dialysis chronic kidney disease patients. Nephron Clin Pract. 2008;110:c244-c250.
29. Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2011;57:2496-2504.